

# Smoldering Multiple Myeloma

Thinking about what to do next?



DO SOMETHING “*more than*” WATCHING AND WAITING

## Join the National Institutes of Health’s Research Study

Smoldering (“asymptomatic”) multiple myeloma (SMM) runs the risk of developing into multiple myeloma: a cancer of the plasma cells that presents with complications of bone fractures, low blood counts, high calcium levels and kidney problems. SMM is currently left untreated until multiple myeloma develops. *Want to do more than watchful waiting?* Scientists at the National Institutes of Health (NIH) National Cancer Institute (NCI) *do!*

One way is by testing a combination of cancer fighting drugs (Carfilzomib, Lenalidomide, and Dexamethasone) in the treatment of high-risk smoldering multiple myeloma. **Come**, partner with leading researchers in their efforts to test this combination for safety and effectiveness against high-risk smoldering multiple myeloma.

### CONTACT

NIH Clinical Center

Office of Patient Recruitment

1-800-411-1222 or [PRPL@cc.nih.gov](mailto:PRPL@cc.nih.gov)  
(Refer to 12-C-0107)

TTY for the deaf and hard of hearing:

1-866-411-1010

<https://go.usa.gov/xUy7r>

***All study-related treatments, tests, and care provided at no cost***

The NIH Clinical Center, America’s Research Hospital, is located in Bethesda, Maryland, on the Metro red line (Medical Center stop).



NATIONAL  
CANCER  
INSTITUTE

NIH...Turning Discoveries into Health®